Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination pharmaceutical product** composed of ketorolac (a nonsteroidal anti-inflammatory drug), isopropyl alcohol (an antiseptic/disinfectant), and lidocaine (a local anesthetic). Ketorolac acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby blocking prostaglandin synthesis to produce analgesic and anti-inflammatory effects[7]. Lidocaine blocks voltage-gated sodium channels in neuronal membranes, preventing pain signal transmission[8]. Isopropyl alcohol serves primarily as a vehicle and antiseptic but does not contribute a pharmacological effect relevant to analgesia[9]. This combination is used for **local injection or regional anesthesia** where rapid and prolonged pain control is desired, often in procedures such as musculoskeletal biopsies and minor surgeries, with evidence showing superior pain control compared to lidocaine alone during the early postoperative period[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac + isopropyl alcohol + lidocaine.